DreaMed Diabetes is a medical device company providing personalized diabetes treatment optimization solutions. The company was established in 2014 and commercialized its first product, GlucoSitter, an artificial pancreas technology which was licensed to Medtronic Diabetes. Ever since, DreaMed Diabetes has been vigorously working on the DreaMed Advisor portfolio, decision support tools in the diabetes management space. DreaMed became the first and only company in the world to receive FDA clearance for DreaMed Advisor Pro, a decision support system in Type I diabetes patients using data from CGM/SMBG and insulin pumps. The company is continuing to develop the DreaMed Advisor portfolio which will aid all people living with diabetes no matter the insulin therapy or diabetes type and their healthcare professionals to provide personalized insulin therapy.

Medical Devices

DreaMed Diabetes

Eran Atlas

Erez Nahshon

Doron Hoffman

Inbar Sagi

Yael Shtrit

Ido Mueller

Ryan Hovey

Noy Ben Moyal

Thomas Danne

Revital Nimri

Tadej Battelino

The Leadership Team at DreaMed Diabetes is responsible for setting the strategic vision and direction of the company, guiding innovation in diabetes management solutions. Composed of co-founders with expertise in medicine and technology, this team drives product development, oversees regulatory compliance, and fosters partnerships to enhance patient care and optimize diabetes treatments through data-driven decision support tools. Their collaborative efforts ensure the company remains at the forefront of advancements in personalized diabetes therapy.

Leadership Team

Engineering and Technology

Human Resources Team

Leadership Team

About

Team members

Other teams at DreaMed Diabetes

Engineering and Technology

Human Resources Team